Literature DB >> 17952490

Percutaneous closure of ventricular septal defect associated with tunnel-shaped aneurysm using the Amplatzer duct occluder.

Muhammad Dilawar1, Mohammed Numan, Amal El-Sisi, Salwa Morcos Gendi, Zaheer Ahmad.   

Abstract

Different devices have been used for percutaneous closure of ventricular septal defects (VSDs). Over the past 6 months, we have used the Amplatzer duct occluder for VSDs associated with tunnel-shaped aneurysm in three patients here at our institution. Due to the anatomic resemblance between such VSDs and the duct occluder, we selected this device for percutaneous closure. There was trivial residual shunt in one patient. All three patients tolerated the procedure well and there were no untoward complications.

Entities:  

Mesh:

Year:  2007        PMID: 17952490     DOI: 10.1007/s00246-007-9092-0

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  18 in total

1.  [Effects of intraoperative hybrid procedures for the treatment of congenital heart disease].

Authors:  Sheng-shou Hu; Shou-jun Li; Hao Zhang; Han-song Sun; Xiang-dong Shen; Hao Wang; Shi-liang Jiang
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2006-03

2.  Transcatheter closure of congenital ventricular septal defect with Amplatzer septal occluders.

Authors:  Mario Carminati; Gianfranco Butera; Massimo Chessa; Manuela Drago; Diana Negura; Luciane Piazza
Journal:  Am J Cardiol       Date:  2005-11-02       Impact factor: 2.778

3.  Clinical course in ventricular septal defect.

Authors:  W H Weidman; S G Blount; J W DuShane; W M Gersony; C J Hayes; A S Nadas
Journal:  Circulation       Date:  1977-08       Impact factor: 29.690

4.  Preoperative evaluation and surgery in isolated ventricular septal defects: a 21 year perspective.

Authors:  A Nygren; J Sunnegårdh; H Berggren
Journal:  Heart       Date:  2000-02       Impact factor: 5.994

5.  Transcatheter closure of perimembranous ventricular septal defects using amplatzer asymmetric ventricular septal defect occluder: preliminary experience with 18-month follow up.

Authors:  Robin J Pinto; Bharat V Dalvi; Satyavan Sharma
Journal:  Catheter Cardiovasc Interv       Date:  2006-07       Impact factor: 2.692

6.  Is complete heart block after surgical closure of ventricular septum defects still an issue?

Authors:  Henrik Ø Andersen; Marc R de Leval; Victor T Tsang; Martin J Elliott; Robert H Anderson; Andrew C Cook
Journal:  Ann Thorac Surg       Date:  2006-09       Impact factor: 4.330

7.  Transcatheter closure of congenital ventricular septal defects: experience with various devices.

Authors:  Ramesh Arora; Vijay Trehan; Ashish Kumar; G S Kalra; Madhuri Nigam
Journal:  J Interv Cardiol       Date:  2003-02       Impact factor: 2.279

8.  Transcatheter closure of congenital muscular ventricular septal defect.

Authors:  Ramesh Arora; Vijay Trehan; Ashish K Thakur; Vimal Mehta; P P Sengupta; M Nigam
Journal:  J Interv Cardiol       Date:  2004-04       Impact factor: 2.279

Review 9.  The incidence of congenital heart disease.

Authors:  Julien I E Hoffman; Samuel Kaplan
Journal:  J Am Coll Cardiol       Date:  2002-06-19       Impact factor: 24.094

10.  Device closure of muscular ventricular septal defects using the Amplatzer muscular ventricular septal defect occluder: immediate and mid-term results of a U.S. registry.

Authors:  Ralf Holzer; David Balzer; Qi-Ling Cao; Ken Lock; Ziyad M Hijazi
Journal:  J Am Coll Cardiol       Date:  2004-04-07       Impact factor: 24.094

View more
  2 in total

1.  Perimembranous Ventricular Septal Defect Device Closure: Choosing Between Amplatzer Duct Occluder I and II.

Authors:  Amal El-Sisi; R Sobhy; V Jaccoub; H Hamza
Journal:  Pediatr Cardiol       Date:  2017-03-01       Impact factor: 1.655

2.  Safety of an improved patent ductus arteriosus occluder for transcatheter closure of perimembranous ventricular septal defects with abnormally attached tricuspid chordae tendineae.

Authors:  Lu He; Ya-Juan Du; Ge-Sheng Cheng; Yu-Shun Zhang
Journal:  World J Clin Cases       Date:  2019-03-06       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.